BioNTech SE (NASDAQ:BNTX) Stock Position Lifted by Slow Capital Inc.

Slow Capital Inc. boosted its stake in BioNTech SE (NASDAQ:BNTX) by 15.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 29,526 shares of the company’s stock after buying an additional 4,012 shares during the quarter. Slow Capital Inc.’s holdings in BioNTech were worth $3,116,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. Baillie Gifford & Co. grew its stake in BioNTech by 15.5% in the third quarter. Baillie Gifford & Co. now owns 8,602,839 shares of the company’s stock valued at $934,612,000 after purchasing an additional 1,152,541 shares in the last quarter. Envestnet Asset Management Inc. increased its holdings in BioNTech by 4,861.2% in the first quarter. Envestnet Asset Management Inc. now owns 972,535 shares of the company’s stock worth $1,531,000 after buying an additional 952,932 shares during the last quarter. BlackRock Inc. raised its position in BioNTech by 25.9% during the first quarter. BlackRock Inc. now owns 1,610,975 shares of the company’s stock valued at $274,768,000 after acquiring an additional 331,101 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in BioNTech in the first quarter valued at approximately $42,711,000. Finally, Point72 Asset Management L.P. grew its position in BioNTech by 175.1% in the fourth quarter. Point72 Asset Management L.P. now owns 302,600 shares of the company’s stock worth $45,457,000 after acquiring an additional 192,600 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Stock Performance

NASDAQ:BNTX traded down $0.46 during trading hours on Wednesday, hitting $85.88. 411,611 shares of the company traded hands, compared to its average volume of 659,572. The company has a current ratio of 9.43, a quick ratio of 9.26 and a debt-to-equity ratio of 0.01. BioNTech SE has a twelve month low of $85.21 and a twelve month high of $125.83. The firm has a 50-day moving average of $91.67 and a 200 day moving average of $97.64. The stock has a market capitalization of $20.42 billion, a price-to-earnings ratio of 20.77 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $2.04 billion. On average, analysts forecast that BioNTech SE will post -1.67 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. HC Wainwright cut their price target on shares of BioNTech from $133.00 to $107.00 and set a “buy” rating on the stock in a report on Tuesday, January 23rd. Oppenheimer began coverage on BioNTech in a report on Friday, January 5th. They set a “market perform” rating on the stock. The Goldman Sachs Group decreased their price target on BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 28th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.00 target price on shares of BioNTech in a research report on Thursday, March 21st. Finally, JPMorgan Chase & Co. reduced their price objective on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a research note on Friday, March 22nd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, BioNTech currently has a consensus rating of “Hold” and a consensus target price of $120.40.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.